You are here

Resources for Researchers

SARC’s resources include access to the SARC Biospecimen Bank, SARC Clinical Data Repository, SARC Imaging Resources, and additional resources including the sarcoma drug response portal. We help multi-institutional research happen. Our aim is to be the catalyst for true translational research, ensuring that bench-to-bedside studies are translated to treatments or therapies for medical practice.

This text will be replaced by an image

SARC RESOURCES

SARC Biospecimen Bank

The SARC Biospecimen Bank is designed to help qualified sarcoma investigators or organizations gain access to de-identified specimens to carry out projects that may explore relevant biomarkers, identify novel therapeutic targets, or make other translational discoveries. The SARC Development Therapeutics Committee (DTC) invites applications to conduct translational research using these materials.

Learn more about the SARC Biospecimen Bank.

SARC Clinical Data Repository

SARC has established a repository of clinical data sets from 12 clinical trials, including more than 1,700 patients.

Learn more about SARC Clinical Data Repository.

SARC Imaging Resources

SARC imaging data collected from two clinical trials is now available to sarcoma researchers for further query.

Learn more about SARC Imaging Resources.

SARC Genomic Portal

To help provide our research community with more direct access to genomic data sets onsarcomas, SARC has provided funds from the Development Therapeutics Committee(DTC)to engage the Translational Genomics Research Institute (TGen) to build and maintain an accessible, user-friendly genomic portal.

The SARC Genomic Portal will be available in 2018.


ADDITIONAL RESOURCES

NCI Formulary

We foster collaboration among investigators, academia, and pharma. The National Cancer Institute (NCI) agent formulary (NCI Formulary) is a public-private partnership between the NCI and pharmaceutical and biotechnology companies with a purpose of providing academic investigators with rapid access to agents or combinations of agents for cancer clinical trial use. Agents within the NCI Formulary are available to investigators at NCI-designated Cancer Centers for the conduct of clinical trials under investigator-held IND, as well as pre-clinical research.

Visit the NCI Formulary website to review the list of available agents

Sarcoma Drug Response Portal

The National Cancer Institute performed a screen of 100 FDA-approved compounds and 345 investigational agents in 63 human and pediatric sarcoma cell lines. Gene expression and miRNA expression is also available. 

See results published at NCBI.
See data publicly available.